WO2021121390A1 - 杂环化合物及其药物组合物、制备方法、中间体和应用 - Google Patents
杂环化合物及其药物组合物、制备方法、中间体和应用 Download PDFInfo
- Publication number
- WO2021121390A1 WO2021121390A1 PCT/CN2020/137618 CN2020137618W WO2021121390A1 WO 2021121390 A1 WO2021121390 A1 WO 2021121390A1 CN 2020137618 W CN2020137618 W CN 2020137618W WO 2021121390 A1 WO2021121390 A1 WO 2021121390A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkyl
- group
- unsubstituted
- independently
- Prior art date
Links
- 0 C1CC*CC1 Chemical compound C1CC*CC1 0.000 description 11
- WVMBISZHWMJNNM-UHFFFAOYSA-N CC(C)c1c[nH]nc1 Chemical compound CC(C)c1c[nH]nc1 WVMBISZHWMJNNM-UHFFFAOYSA-N 0.000 description 2
- SEALQMGWGRANQK-CQQBXOTJSA-N CC(C)c1cnc(c(NC(CC2)CCN2C(O[C@@H](CC2)CN2C(/C=C/CN(C)C)=O)=O)n2)[n]1nc2OC(C)C Chemical compound CC(C)c1cnc(c(NC(CC2)CCN2C(O[C@@H](CC2)CN2C(/C=C/CN(C)C)=O)=O)n2)[n]1nc2OC(C)C SEALQMGWGRANQK-CQQBXOTJSA-N 0.000 description 2
- JMRLLDGYAPGWNM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1Nc1nc(/S(/C)=C/C)n[n]2c1ncc2)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1Nc1nc(/S(/C)=C/C)n[n]2c1ncc2)=O JMRLLDGYAPGWNM-UHFFFAOYSA-N 0.000 description 1
- RQYBEGMVONXYBV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1Nc1nc(/S(/C)=C\C)n[n]2c1ncc2Br)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1Nc1nc(/S(/C)=C\C)n[n]2c1ncc2Br)=O RQYBEGMVONXYBV-UHFFFAOYSA-N 0.000 description 1
- APCBTRDHCDOPNY-ZETCQYMHSA-N CC(C)(C)OC(N(CC1)C[C@H]1O)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]1O)=O APCBTRDHCDOPNY-ZETCQYMHSA-N 0.000 description 1
- FRNFPCYOEBNDIQ-UHFFFAOYSA-N CC(C)Oc(nc1NC(CC2)CCN2C(OC(C)(C)C)=O)n[n]2c1ncc2Br Chemical compound CC(C)Oc(nc1NC(CC2)CCN2C(OC(C)(C)C)=O)n[n]2c1ncc2Br FRNFPCYOEBNDIQ-UHFFFAOYSA-N 0.000 description 1
- SCWWRXHPQVPPGY-UHFFFAOYSA-N CC(C)Oc(nc1NC(CC2)CCN2C(OC(C)(C)C)=O)n[n]2c1ncc2C(C)=C Chemical compound CC(C)Oc(nc1NC(CC2)CCN2C(OC(C)(C)C)=O)n[n]2c1ncc2C(C)=C SCWWRXHPQVPPGY-UHFFFAOYSA-N 0.000 description 1
- ZPAUTYJGAPNIAZ-UHFFFAOYSA-N CC(C)[n]1c(nc(cc2NC(CC3)CCN3C(OC(C)(C)C)=O)Cl)c2nc1 Chemical compound CC(C)[n]1c(nc(cc2NC(CC3)CCN3C(OC(C)(C)C)=O)Cl)c2nc1 ZPAUTYJGAPNIAZ-UHFFFAOYSA-N 0.000 description 1
- MJVGUNYXCQTECX-UHFFFAOYSA-N CC(C)[n]1c2nc(C(C)=C)cc(NC(CC3)CCN3C(OC(C)(C)C)=O)c2nc1 Chemical compound CC(C)[n]1c2nc(C(C)=C)cc(NC(CC3)CCN3C(OC(C)(C)C)=O)c2nc1 MJVGUNYXCQTECX-UHFFFAOYSA-N 0.000 description 1
- QIKMLJWIAVFZRC-UHFFFAOYSA-N CC(C)[n]1c2nc(C)cc(C)c2nc1 Chemical compound CC(C)[n]1c2nc(C)cc(C)c2nc1 QIKMLJWIAVFZRC-UHFFFAOYSA-N 0.000 description 1
- FICGNBSSGRMFIO-UHFFFAOYSA-N CC(C)[n]1c2nc(Cl)cc(Cl)c2nc1 Chemical compound CC(C)[n]1c2nc(Cl)cc(Cl)c2nc1 FICGNBSSGRMFIO-UHFFFAOYSA-N 0.000 description 1
- WGVLSMHFZAGTBR-DORXLWPQSA-N CC(C)c(cc1NC(CC2)CCN2C(O[C@@H](CC2)CN2C(/C=C/CN(C)C)=O)=O)nc2c1nc[n]2C(C)C Chemical compound CC(C)c(cc1NC(CC2)CCN2C(O[C@@H](CC2)CN2C(/C=C/CN(C)C)=O)=O)nc2c1nc[n]2C(C)C WGVLSMHFZAGTBR-DORXLWPQSA-N 0.000 description 1
- ZAZNOPZSYQGRON-UHFFFAOYSA-N CC(C)c1c(C)nc(c(NC2CCNCC2)n2)[n]1nc2OC(C)C Chemical compound CC(C)c1c(C)nc(c(NC2CCNCC2)n2)[n]1nc2OC(C)C ZAZNOPZSYQGRON-UHFFFAOYSA-N 0.000 description 1
- GRDAHPJRLCTJNA-BXKJMJEDSA-N CC(C)c1c2nc(C)cc(NC(CC3)CCN3C(O[C@@H](CC3)CN3C(/C=C/CN(C)C)=O)=O)[n]2nc1 Chemical compound CC(C)c1c2nc(C)cc(NC(CC3)CCN3C(O[C@@H](CC3)CN3C(/C=C/CN(C)C)=O)=O)[n]2nc1 GRDAHPJRLCTJNA-BXKJMJEDSA-N 0.000 description 1
- GRDAHPJRLCTJNA-IRUYWQDXSA-N CC(C)c1c2nc(C)cc(NC(CC3)CCN3C(O[C@H](CC3)CN3C(/C=C/CN(C)C)=O)=O)[n]2nc1 Chemical compound CC(C)c1c2nc(C)cc(NC(CC3)CCN3C(O[C@H](CC3)CN3C(/C=C/CN(C)C)=O)=O)[n]2nc1 GRDAHPJRLCTJNA-IRUYWQDXSA-N 0.000 description 1
- XKNQJVGYHCVLRZ-UHFFFAOYSA-N CC(C)c1cc(C(C)C)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1cc(C(C)C)nc2c1nc[n]2C(C)C XKNQJVGYHCVLRZ-UHFFFAOYSA-N 0.000 description 1
- JTXYSBMIDNCJBG-UHFFFAOYSA-N CC(C)c1cc(NC(C)C)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1cc(NC(C)C)nc2c1nc[n]2C(C)C JTXYSBMIDNCJBG-UHFFFAOYSA-N 0.000 description 1
- ZECPYLLTVBNZPF-UHFFFAOYSA-N CC(C)c1cc(NC(CC2)CCN2C(OC(C)(C)C)=O)c2nc[n](C(C)C)c2n1 Chemical compound CC(C)c1cc(NC(CC2)CCN2C(OC(C)(C)C)=O)c2nc[n](C(C)C)c2n1 ZECPYLLTVBNZPF-UHFFFAOYSA-N 0.000 description 1
- PYAJCQDLVFDMQC-FQEVSTJZSA-N CC(C)c1cc(NC(CC2)CCN2C(O[C@@H](CC2)CN2C(OC(C)(C)C)=O)=O)c2nc[n](C(C)C)c2n1 Chemical compound CC(C)c1cc(NC(CC2)CCN2C(O[C@@H](CC2)CN2C(OC(C)(C)C)=O)=O)c2nc[n](C(C)C)c2n1 PYAJCQDLVFDMQC-FQEVSTJZSA-N 0.000 description 1
- HHYNHHJSVDIGKS-KRWDZBQOSA-N CC(C)c1cc(NC(CC2)CCN2C(O[C@@H]2CNCC2)=O)c2nc[n](C(C)C)c2n1 Chemical compound CC(C)c1cc(NC(CC2)CCN2C(O[C@@H]2CNCC2)=O)c2nc[n](C(C)C)c2n1 HHYNHHJSVDIGKS-KRWDZBQOSA-N 0.000 description 1
- SYIHSFQKDCGXEN-UHFFFAOYSA-N CC(C)c1cc(NC2CC2)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1cc(NC2CC2)nc2c1nc[n]2C(C)C SYIHSFQKDCGXEN-UHFFFAOYSA-N 0.000 description 1
- JSIOCLILEFIDJU-UHFFFAOYSA-N CC(C)c1cc(NC2CCNCC2)c2nc[n](C(C)C)c2n1 Chemical compound CC(C)c1cc(NC2CCNCC2)c2nc[n](C(C)C)c2n1 JSIOCLILEFIDJU-UHFFFAOYSA-N 0.000 description 1
- KTTSYFCPFCWNNZ-UHFFFAOYSA-N CC(C)c1cc(NCCN(C)C)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1cc(NCCN(C)C)nc2c1nc[n]2C(C)C KTTSYFCPFCWNNZ-UHFFFAOYSA-N 0.000 description 1
- UKYVWMRXJVXJKU-UHFFFAOYSA-N CC(C)c1cc(NCCO)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1cc(NCCO)nc2c1nc[n]2C(C)C UKYVWMRXJVXJKU-UHFFFAOYSA-N 0.000 description 1
- POCOTGPZDWDOEG-UHFFFAOYSA-N CC(C)c1cc(NCCOC)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1cc(NCCOC)nc2c1nc[n]2C(C)C POCOTGPZDWDOEG-UHFFFAOYSA-N 0.000 description 1
- CKNSWTHXHQYIAH-UHFFFAOYSA-N CC(C)c1ccnc2c1nc[n]2C(C)C Chemical compound CC(C)c1ccnc2c1nc[n]2C(C)C CKNSWTHXHQYIAH-UHFFFAOYSA-N 0.000 description 1
- PKIVXIUNDHLARU-UHFFFAOYSA-N CC(C)c1cnc(c(NC(CC2)CCN2C(OC(C)(C)C)=O)n2)[n]1nc2OC(C)C Chemical compound CC(C)c1cnc(c(NC(CC2)CCN2C(OC(C)(C)C)=O)n2)[n]1nc2OC(C)C PKIVXIUNDHLARU-UHFFFAOYSA-N 0.000 description 1
- VMTHSJAPVWERJP-IBGZPJMESA-N CC(C)c1cnc(c(NC(CC2)CCN2C(O[C@@H](CC2)CN2C(OC(C)(C)C)=O)=O)n2)[n]1nc2OC(C)C Chemical compound CC(C)c1cnc(c(NC(CC2)CCN2C(O[C@@H](CC2)CN2C(OC(C)(C)C)=O)=O)n2)[n]1nc2OC(C)C VMTHSJAPVWERJP-IBGZPJMESA-N 0.000 description 1
- NIFJBNWPQTUXGK-INIZCTEOSA-N CC(C)c1cnc(c(NC(CC2)CCN2C(O[C@@H]2CNCC2)=O)n2)[n]1nc2OC(C)C Chemical compound CC(C)c1cnc(c(NC(CC2)CCN2C(O[C@@H]2CNCC2)=O)n2)[n]1nc2OC(C)C NIFJBNWPQTUXGK-INIZCTEOSA-N 0.000 description 1
- ZICRALLMHKILDG-UHFFFAOYSA-N CC(C)c1n[nH]cc1 Chemical compound CC(C)c1n[nH]cc1 ZICRALLMHKILDG-UHFFFAOYSA-N 0.000 description 1
- UXPYHCSHGMLMLP-UHFFFAOYSA-N CC(C)c1nc(COC)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1nc(COC)nc2c1nc[n]2C(C)C UXPYHCSHGMLMLP-UHFFFAOYSA-N 0.000 description 1
- ZUSRLBXBDDBZHE-UHFFFAOYSA-N CC(C)c1nc(N(C2)CC2OC)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1nc(N(C2)CC2OC)nc2c1nc[n]2C(C)C ZUSRLBXBDDBZHE-UHFFFAOYSA-N 0.000 description 1
- DJKAINADJWZKIN-UHFFFAOYSA-N CC(C)c1nc(NC2CC2)nc2c1nc[n]2C(C)C Chemical compound CC(C)c1nc(NC2CC2)nc2c1nc[n]2C(C)C DJKAINADJWZKIN-UHFFFAOYSA-N 0.000 description 1
- SVSUYEJKNSMKKW-UHFFFAOYSA-N CC1(C)OB(C(C)=C)OC1(C)C Chemical compound CC1(C)OB(C(C)=C)OC1(C)C SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 1
- QAFODUGVXFNLBE-UHFFFAOYSA-N CCC(COC)N Chemical compound CCC(COC)N QAFODUGVXFNLBE-UHFFFAOYSA-N 0.000 description 1
- BPVDJYYMAXDIEM-UHFFFAOYSA-N CCC(CO[IH]CC(C)N)NC(C)C Chemical compound CCC(CO[IH]CC(C)N)NC(C)C BPVDJYYMAXDIEM-UHFFFAOYSA-N 0.000 description 1
- OZSXLBQDGSTEDA-XBXARRHUSA-N CCC(C[O]#C)/C=N/N Chemical compound CCC(C[O]#C)/C=N/N OZSXLBQDGSTEDA-XBXARRHUSA-N 0.000 description 1
- HHZREYAIWSZPGE-SSDOTTSWSA-N CC[C@H](CO)NC(C)C Chemical compound CC[C@H](CO)NC(C)C HHZREYAIWSZPGE-SSDOTTSWSA-N 0.000 description 1
- OVXGMXYATJGQPQ-GFCCVEGCSA-N CC[C@H](CO)Nc(cc1C(C)C)nc2c1nc[n]2C(C)C Chemical compound CC[C@H](CO)Nc(cc1C(C)C)nc2c1nc[n]2C(C)C OVXGMXYATJGQPQ-GFCCVEGCSA-N 0.000 description 1
- OHYAFTVJAISTPZ-XASFLLNLSA-N CC[C@H](CO)Nc1nc2c(C(C)C)cn[n]2c(NC(CC2)CCN2C(O[C@@H](CC2)CN2C(/C=C/CN(C)C)=O)=O)n1 Chemical compound CC[C@H](CO)Nc1nc2c(C(C)C)cn[n]2c(NC(CC2)CCN2C(O[C@@H](CC2)CN2C(/C=C/CN(C)C)=O)=O)n1 OHYAFTVJAISTPZ-XASFLLNLSA-N 0.000 description 1
- XUDMNEVPRUULLH-UHFFFAOYSA-N CC[n]1c2nccc(C(C)C)c2nc1 Chemical compound CC[n]1c2nccc(C(C)C)c2nc1 XUDMNEVPRUULLH-UHFFFAOYSA-N 0.000 description 1
- IHNXHUNMFYXQCG-UHFFFAOYSA-N CCc1c[nH]nc1 Chemical compound CCc1c[nH]nc1 IHNXHUNMFYXQCG-UHFFFAOYSA-N 0.000 description 1
- XBLGEGUCSFXPHJ-UHFFFAOYSA-N IOC1CNC1 Chemical compound IOC1CNC1 XBLGEGUCSFXPHJ-UHFFFAOYSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1OC(Cl)=O)=O Chemical compound [O-][N+](c(cc1)ccc1OC(Cl)=O)=O NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Definitions
- the present invention relates to a heterocyclic compound and its pharmaceutical composition, preparation method, intermediate and application.
- Cyclin-dependent kinases belong to the serine/threonine kinase family.
- the monomer itself is not active, and must be combined with the corresponding cyclins (Cyclins) to form active heterodimerization
- the body complex plays a regulatory role and can catalyze the phosphorylation of the corresponding substrate, directly or indirectly regulate the cell to complete the cell cycle, and cause the growth and proliferation of the cell. It has been found that the human genome encodes 21 CDKs and more than 15 Cyclins. According to their different functions, CDKs can be divided into two categories: CDKs that control the cell cycle and CDKs that control cell transcription.
- CDK 1/2/4/6 is mainly related to the cell cycle
- CDK 7/8/9/10 is mainly related to the transcription mechanism of genetic information in the cell (Asghar U, Witkiewicz AK, Turner N C, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov, 2015(2): 130-146).
- CDK7 is an important member of the CDKs family. It mainly regulates the cell cycle in two indirect ways: CDK7, cyclin H and Mat1 together form CAK (CDK activating kinase), which further phosphorylates CDK1/2, thereby activating them in Functions in the cell cycle (Yee A, Nichols MA, Wu L, Hall FL, Kobayashi R, Xiong Y. Molecular cloning of CDK7-associated human MAT1, a cyclin-dependent kinase-activating kinase (CAK) assembly factor.Cancer Res. 1995; 55:6058–6062).
- CAK cyclin-dependent kinase-activating kinase
- CDK7 is a subunit component of the universal transcription factor TFIIH to phosphorylate the large subunit carboxyl terminal domain (CTD) of RNA polymerase II (RNA polymerase II, RNAP II) to regulate the process of gene transcription in cells ( Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S et al.Cyclin-dependentkinase 7controls mRNA synthesis by affecting stability of preinitiationcomplexes, leading to cell progression, cell Mol Cell Biol. 2014; 34: 3675-3688.). Since CDK7 has the dual functions of CAK and CTD phosphorylation, it plays an important role in cell proliferation, cell cycle and transcription.
- CTD carboxyl terminal domain
- CDK7 Inhibition of CDK7 can inhibit the expression of key oncogenes such as c-Myc (Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven .Cell.2014,159:1126–39).
- c-Myc Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven .Cell.2014,159:1126–39).
- CDK7 inhibitors may also be effective against cancers that have developed resistance to current treatment methods. Therefore, the development of CDK7 inhibitors will likely become an effective means of treating these malignant tumors.
- the CDK7 inhibitors that have been reported include THZ1, Syros's compound SY-1365, and Carrick's compound CT7001, etc.
- the structure is as follows:
- Example 1 and Example 3 of Lilly's patent application WO2019099298A1 disclose two CDK7 inhibitors.
- the compound structures are as follows:
- the technical problem to be solved by the present invention is that the structure of the existing CDK7 inhibitor is relatively simple, so the present application provides a heterocyclic compound with a new structure and its pharmaceutical composition, preparation method, intermediate and application.
- the heterocyclic compound of the present invention has a better inhibitory effect on CDK7, and can be used to treat tumors and other diseases.
- the present invention provides a compound represented by formula I:
- ring A is
- X is O or NR a ;
- R a is hydrogen, methyl or ethyl
- n 1 or 2;
- n 1, 2 or 3;
- R 1 is (E.g )or
- R 2 is hydrogen or C 1-6 alkyl
- R 3 is hydrogen or C 1-6 alkyl
- R 4 is hydrogen, halogen, C 1-6 alkyl or -CH 2 -NR 4a R 4b (for example, -CH 2 -N(CH 3 ) 2 );
- R 4a and R 4b are each independently hydrogen or C 1-6 alkyl (such as methyl); alternatively, R 4a and R 4b together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkane
- the 4-6 membered heterocycloalkyl group has 0, 1, or 2 additional heteroatoms independently selected from N, O, and S, and the substituted 4-6 membered heterocycloalkyl group refers to the 4-
- the 6-membered heterocycloalkyl group is substituted with 1, 2, 3 or 4 R b ;
- Each R b is independently halogen, hydroxy or C 1-4 alkyl
- R 5 is hydrogen or C 1-6 alkyl (e.g. methyl);
- Each R 6 is independently hydrogen, cyclopropyl or C 1-6 alkyl (for example methyl, ethyl, n-propyl or isopropyl, preferably isopropyl);
- Each R 7 is independently hydrogen, substituted or unsubstituted C 1-6 alkyl (the C 1-6 alkyl such as methyl, ethyl or isopropyl; further, the substituted or unsubstituted C 1-6 alkyl such as methyl, ethyl, isopropyl or -CH 2 OH), substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 membered heteroaryl (the 5-6 member Heteroaryl groups such as pyrazolyl, such as Further, the substituted or unsubstituted 5-6 membered heteroaryl group is for example ), substituted or unsubstituted C 3-6 cycloalkyl (e.g.
- the substituted C 1-6 alkyl, substituted phenyl, substituted C 3-6 cycloalkyl and substituted 5-6 membered heteroaryl refer to the C 1-6 alkyl, benzene Group, C 3-6 cycloalkyl group and 5-6 membered heteroaryl group are each independently substituted with 1, 2, 3, or 4 R 7d (for example, substituted by 1 R 7d );
- Each R 7d is independently hydroxy, halogen, C 1-4 alkyl, -NR a1 R a2 (e.g. -N(CH 3 ) 2 ) or C 1-4 alkoxy (e.g. methoxy);
- R 7a is hydrogen, substituted or unsubstituted C 1-6 alkyl (the C 1-6 alkyl is for example isopropyl; further, the substituted or unsubstituted C 1-6 alkyl is isopropyl ), substituted or unsubstituted C 3-6 cycloalkyl (the C 3-6 cycloalkyl is, for example, cyclopropyl; further, the substituted or unsubstituted C 3-6 cycloalkyl is, for example, cyclopropyl Group), substituted or unsubstituted 4-6 membered heterocycloalkyl or substituted or unsubstituted 5-6 membered heteroaryl, the substituted C 1-6 alkyl, substituted C 3-6 cycloalkyl , Substituted 4-6 membered heterocycloalkyl and substituted 5-6 membered heteroaryl refers to the C 1-6 alkyl, C 3-6 cycloalkyl, 4-6 membered
- Each R c is independently hydroxyl, halogen, C 1-4 alkyl, -NR c1 R c2 (e.g. -N(CH 3 ) 2 ) or C 1-4 alkoxy (e.g. methoxy);
- R 7b and R 7c are each independently hydrogen, substituted or unsubstituted C 1-4 alkyl (the C 1-4 alkyl such as ethyl, isopropyl or sec-butyl; further, the substituted or Unsubstituted C 1-4 alkyl such as ethyl, isopropyl, among them E.g ), Substituted or unsubstituted C 3-6 cycloalkyl (said C 3-6 cycloalkyl such as cyclopropyl or cyclopentyl; Further, the substituted or unsubstituted C 3- 6 cycloalkyl For example cyclopropyl or among them E.g ), substituted or unsubstituted 4-6 membered heterocycloalkyl or substituted or unsubstituted 5-6 membered heteroaryl (the 5-6 membered heteroaryl group is for example pyrazolyl, for example Further, the substituted or unsubstituted 5-6
- R 7b and R 7c together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkyl (the 4-6 membered heterocycloalkyl is for example azetidinyl; further, the The substituted or unsubstituted 4-6 membered heterocycloalkyl group is for example ), the 4-6 membered heterocycloalkyl has 0, 1, or 2 additional heteroatoms independently selected from N, O and S, and the substituted 4-6 membered heterocycloalkyl refers to the 4- The 6-membered heterocycloalkyl group is substituted with 1, 2, 3, or 4 R e (for example, substituted by 1 R e );
- Each Rd is independently hydroxyl, halogen, C 1-4 alkyl, -NR d1 R d2 (for example -N(CH 3 ) 2 ) or C 1-4 alkoxy (for example methoxy);
- Each R e is independently hydroxy, halogen, C 1-4 alkyl, -NR e1 R e2 or C 1-4 alkoxy (for example, methoxy);
- R a1 , R a2 , R c1 , R c2 , R d1 , R d2 , R e1 and R e2 is independently hydrogen or C 1-4 alkyl (e.g. methyl);
- Each R 8 is independently hydrogen or C 1-4 alkyl (e.g. methyl);
- the number of heteroatoms in the 4-6 membered heterocycloalkyl group and 5-6 membered heteroaryl group is independently 1, 2, or 3, and each heteroatom is independently selected from N, O, and S.
- each R 7 is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 membered heteroaryl, -OR 7a or -NR 7b R 7c , the substituted C 1-6 alkyl, substituted phenyl and substituted 5-6 membered heteroaryl refer to the C 1-6 alkyl, phenyl and 5- The 6-membered heteroaryl groups are each independently substituted with 1, 2, 3, or 4 R 7d .
- the compound represented by Formula I is defined as follows:
- ring A is
- X is O or NR a ;
- R a is hydrogen, methyl or ethyl
- n 1 or 2;
- n 1, 2 or 3;
- R 1 is (E.g )or
- R 2 is hydrogen or C 1-6 alkyl
- R 3 is hydrogen or C 1-6 alkyl
- R 4 is hydrogen, halogen, C 1-6 alkyl or -CH 2 -NR 4a R 4b (for example, -CH 2 -N(CH 3 ) 2 );
- R 4a and R 4b are each independently hydrogen or C 1-6 alkyl (such as methyl); alternatively, R 4a and R 4b together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkane
- the 4-6 membered heterocycloalkyl group has 0, 1, or 2 additional heteroatoms independently selected from N, O, and S, and the substituted 4-6 membered heterocycloalkyl group refers to the 4-
- the 6-membered heterocycloalkyl is substituted with 1, 2, 3 or 4 R b ;
- Each R b is independently halogen, hydroxy or C 1-4 alkyl
- R 5 is hydrogen or C 1-6 alkyl (e.g. methyl);
- Each R 6 is independently hydrogen, cyclopropyl or C 1-6 alkyl (for example methyl, ethyl, n-propyl or isopropyl, preferably isopropyl);
- Each R 7 is independently hydrogen, C 1-6 alkyl, phenyl, 5-6 membered heteroaryl (e.g. pyrazolyl, e.g. ), -OR 7a or -NR 7b R 7c (e.g. among them E.g );
- the number of heteroatoms in the 5-6 membered heteroaryl group is 1, 2 or 3, and each heteroatom is independently selected from N, O and S;
- R 7a is hydrogen or a substituted or unsubstituted C 1-6 alkyl group, and the substituted C 1-6 alkyl group means that the C 1-6 alkyl group is substituted by 1, 2, 3 or 4 R c;
- Each R c is independently hydroxy, halogen, C 1-4 alkyl or C 1-4 alkoxy;
- R 7b and R 7c are each independently hydrogen or substituted or unsubstituted C 1-4 alkyl (the substituted or unsubstituted C 1-4 alkyl such as ethyl, isopropyl, among them E.g ), the substituted C 1-4 alkyl group means that the C 1-4 alkyl group is substituted by 1, 2, 3 or 4 R d;
- R 7b and R 7c together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkyl (the 4-6 membered heterocycloalkyl group is for example azetidinyl), the 4
- the 6-membered heterocycloalkyl has 0, 1, or 2 additional heteroatoms independently selected from N, O, and S, and the substituted 4-6 membered heterocycloalkyl refers to the 4-6 membered heterocycloalkane The group is substituted by 1, 2, 3 or 4 R e ;
- Each R d is independently hydroxy, halogen, C 1-4 alkyl or C 1-4 alkoxy;
- Each R e is independently hydroxy, halogen, C 1-4 alkyl or C 1-4 alkoxy;
- Each R 8 is independently hydrogen or C 1-4 alkyl (e.g. methyl);
- the carbon atom marked with * When the carbon atom marked with * has chirality, it is in the S configuration, R configuration, or a mixture of the two.
- ring A is The definitions of other variables are as described in any aspect of the present invention.
- ring A is The definitions of other variables are as described in any aspect of the present invention.
- ring A is The definitions of other variables are as described in any aspect of the present invention.
- ring A is The definitions of other variables are as described in any aspect of the present invention.
- ring A is The definitions of other variables are as described in any aspect of the present invention.
- ring A is The definitions of other variables are as described in any aspect of the present invention.
- ring A is The definitions of other variables are as described in any aspect of the present invention.
- the preferred ring A is The definitions of other variables are as described in any aspect of the present invention.
- the compounds I as shown in the formula, R a is hydrogen, the other variables are as defined in the present invention, any of the aspects.
- n 1
- the definitions of other variables are as described in any of the embodiments of the present invention.
- R 2 is hydrogen, and other variables are defined as described in any of the embodiments of the present invention.
- R 3 is hydrogen, and other variables are defined as described in any of the embodiments of the present invention.
- R 4 is -CH 2 -NR 4a R 4b , and the definitions of other variables are as described in any aspect of the present invention.
- R 4a is a C 1-6 alkyl group, and other variables are defined as described in any of the embodiments of the present invention.
- R 4b is a C 1-6 alkyl group, and the definitions of other variables are as described in any of the embodiments of the present invention.
- R 4 is -CH 2 -N(CH 3 ) 2 , and the definitions of other variables are as described in any aspect of the present invention.
- R 5 is a C 1-6 alkyl group, and other variables are defined as described in any of the embodiments of the present invention.
- each R 7d is independently hydroxyl, -NR a1 R a2 or C 1-4 alkoxy, and other variables are defined as any of the present invention As described in the protocol.
- R 7d is a hydroxyl group.
- R a1 and R a2 are C 1-4 alkyl groups, and the definitions of other variables are as described in any of the embodiments of the present invention.
- each R c is independently hydroxyl, -NR c1 R c2 or C 1-4 alkoxy, and other variables are defined as any of the present invention As described in the protocol.
- R c1 and R c2 are C 1-4 alkyl groups, and the definitions of other variables are as described in any of the embodiments of the present invention.
- R c is a hydroxyl group, and other variables are defined as described in any of the embodiments of the present invention.
- each R d is independently hydroxyl, -NR d1 R d2 or C 1-4 alkoxy, and other variables are defined as any of the present invention As described in the protocol.
- the compounds I as shown in the formula, R d1 and R d2 is C 1-4 alkyl, other variables defined as any one of the present invention embodiment.
- R d is a hydroxyl group, and the definitions of other variables are as described in any of the embodiments of the present invention.
- each R e is independently hydroxy, -NR e1 R e2 or C 1-4 alkoxy, and other variables are defined as any of the present invention As described in the protocol.
- R e1 and R e2 are C 1-4 alkyl groups, and the definitions of other variables are as described in any of the embodiments of the present invention.
- the compounds I as shown in the formula, R e is hydroxy, the other variables are as defined in the present invention, any of the aspects.
- each R 6 is independently hydrogen or C 1-6 alkyl, and other variables are defined as described in any of the embodiments of the present invention.
- each R 7 is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted 5-6 membered heteroaryl Group, -OR 7a or -NR 7b R 7c , the substituted C 1-6 alkyl group and the substituted 5-6 membered heteroaryl group refer to the C 1-6 alkyl group and the 5-6 membered heteroaryl group
- the groups are each independently substituted with 1, 2, 3, or 4 R 7d (for example, by 1 R 7d ), and the definition of other variables is as described in any aspect of the present invention.
- R 7a is hydrogen, substituted or unsubstituted C 1-6 alkyl or substituted or unsubstituted C 3-6 cycloalkyl, said
- the substituted C 1-6 alkyl group and the substituted C 3-6 cycloalkyl group mean that the C 1-6 alkyl group and the C 3-6 cycloalkyl group are each independently covered by 1, 2, 3, or 4 R c Substitution (for example, substitution with 1 R c ), and the definition of other variables are as described in any aspect of the present invention.
- R 7b and R 7c are each independently hydrogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 3-6 Cycloalkyl or substituted or unsubstituted 5-6 membered heteroaryl
- the substituted C 1-4 alkyl, substituted C 3-6 cycloalkyl and substituted 5-6 membered heteroaryl refer to the The C 1-4 alkyl group, C 3-6 cycloalkyl group and 5-6 membered heteroaryl group are each independently substituted by 1, 2, 3, or 4 Rd (for example, substituted by 1 Rd ), and other variables
- the definition of is as described in any aspect of the present invention.
- one of R 7b and R 7c is hydrogen, and other variables are defined as described in any of the embodiments of the present invention.
- each R 7 is independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl or -NR 7b R 7c , the definition of other variables is as described in any aspect of the present invention.
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is a substituted or unsubstituted C 1-6 alkyl group (the C 1-6 alkyl group is for example a methyl group, and the substituted or unsubstituted C 1-6 alkyl group is for example a methyl group), -OR 7a (e.g. ) Or -NR 7b R 7c (e.g. );
- the substituted C 1-6 alkyl group means that the C 1-6 alkyl group is substituted by 1, 2, 3, or 4 R 7d (for example, substituted by 1 R 7d );
- R 7a is hydrogen, a substituted or unsubstituted C 1-6 alkyl group (the C 1-6 alkyl group is, for example, isopropyl; further, the substituted or unsubstituted C 1-6 alkyl group is, for example, isopropyl Group) or substituted or unsubstituted C 3-6 cycloalkyl (the C 3-6 cycloalkyl group is, for example, cyclopropyl; further, the substituted or unsubstituted C 3-6 cycloalkyl group is, for example, cyclo propyl), a substituted C 1- 6 alkyl and substituted C 3-6 cycloalkyl refers to a C 1-6 alkyl and C 3-6 cycloalkyl are each independently 1, 2, 3 or 4 R c substitutions (for example, 1 R c substitution);
- R 7b and R 7c are each independently hydrogen, substituted or unsubstituted C 1-4 alkyl (the C 1-4 alkyl is, for example, ethyl or isopropyl; further, the substituted or unsubstituted C 1-4 alkyl such as ethyl, isopropyl or ) Or substituted or unsubstituted C 3-6 cycloalkyl (the C 3-6 cycloalkyl group is, for example, cyclopropyl; further, the substituted or unsubstituted C 3-6 cycloalkyl group is, for example, cyclopropyl ), the substituted C 1-4 alkyl group and the substituted C 3-6 cycloalkyl group mean that the C 1-4 alkyl group and C 3-6 cycloalkyl group are divided by 1, 2, 3 or 4 R d substitution (for example, 1 R d substitution);
- R 7b and R 7c together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkyl (the 4-6 membered heterocycloalkyl is for example azetidinyl; further, the The substituted or unsubstituted 4-6 membered heterocycloalkyl group is for example ), the 4-6 membered heterocycloalkyl has 0, 1, or 2 additional heteroatoms independently selected from N, O and S, and the substituted 4-6 membered heterocycloalkyl refers to the 4- The 6-membered heterocycloalkyl group is substituted with 1, 2, 3, or 4 R e (for example, substituted by 1 R e );
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is C 1-6 alkyl (e.g. methyl) or -NR 7b R 7c (e.g. );
- R 7b and R 7c are each independently hydrogen or a substituted or unsubstituted C 1-4 alkyl group.
- the substituted C 1-4 alkyl group means that the C 1-4 alkyl group is substituted by 1, 2, 3, or 4 R d substitutions;
- R 7b and R 7c together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkyl group, the 4-6 membered heterocycloalkyl group having 0, 1, or 2 independently selected from N , O and S additional heteroatoms, the substituted 4-6-membered heterocycloalkyl group means that the 4--6 membered heterocycloalkyl group is substituted with 1, 2, 3, or 4 R e ;
- R 8 is hydrogen
- R 6 , R 7 and R 8 are preferably as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is C 1-6 alkyl (e.g. methyl);
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. ethyl or isopropyl);
- R 7 is hydrogen, a substituted or unsubstituted C 1-6 alkyl group (the C 1-6 alkyl group is, for example, methyl or ethyl; further, the substituted or unsubstituted C 1-6 alkyl group is, for example, methyl Group, ethyl or -CH 2 OH), substituted or unsubstituted 5-6 membered heteroaryl (the 5-6 membered heteroaryl group such as pyrazolyl, for example Further, the substituted or unsubstituted 5-6 membered heteroaryl group is for example ) Or -NR 7b R 7c (e.g.
- the substituted C 1-6 alkyl group and the substituted 5-6 membered heteroaryl group means that the C 1-6 alkyl group and the 5-6 membered heteroaryl group are each independently covered by 1, 2, 3 Or 4 R 7d substitutions (for example, 1 R 7d substitution);
- R 7b and R 7c are each independently hydrogen, substituted or unsubstituted C 1-4 alkyl (the C 1-4 alkyl is, for example, isopropyl or sec-butyl; further, the substituted or unsubstituted C 1-4 alkyl such as isopropyl or among them E.g ) Or substituted or unsubstituted C 3-6 cycloalkyl (the C 3-6 cycloalkyl group is, for example, cyclopropyl; further, the substituted or unsubstituted C 3-6 cycloalkyl group is, for example, cyclopropyl ), the substituted C 1-4 alkyl group and the substituted C 3-6 cycloalkyl group mean that the C 1-4 alkyl group and C 3-6 cycloalkyl group are each independently covered by 1, 2, 3 or 4 R d substitutions (for example, 1 R d substitution); preferably, one of R 7b and R 7c is hydrogen;
- R 7b and R 7c together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkyl (the 4-6 membered heterocycloalkyl is for example azetidinyl; further, the The substituted or unsubstituted 4-6 membered heterocycloalkyl group is for example ), the 4-6 membered heterocycloalkyl has 0, 1, or 2 additional heteroatoms independently selected from N, O and S, and the substituted 4-6 membered heterocycloalkyl refers to the 4- The 6-membered heterocycloalkyl group is substituted with 1, 2, 3, or 4 R e (for example, substituted by 1 R e );
- R 8 is hydrogen or C 1-4 alkyl (e.g. methyl), preferably hydrogen;
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. ethyl or isopropyl);
- R 7 is hydrogen, C 1-6 alkyl (such as methyl), 5-6 membered heteroaryl (such as pyrazolyl, such as ) Or -NR 7b R 7c (e.g. among them E.g );
- R 7a is hydrogen or a substituted or unsubstituted C 1-6 alkyl group, and the substituted C 1-6 alkyl group means that the C 1-6 alkyl group is substituted by 1, 2, 3 or 4 R c;
- R 7b and R 7c are each independently hydrogen or a substituted or unsubstituted C 1-4 alkyl group.
- the substituted C 1-4 alkyl group means that the C 1-4 alkyl group is substituted by 1, 2, 3, or 4 R d substitutions;
- R 7b and R 7c together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkyl group, the 4-6 membered heterocycloalkyl group having 0, 1, or 2 independently selected from N , O and S additional heteroatoms, the substituted 4-6 membered heterocycloalkyl group means that the 4-6 membered heterocycloalkyl group is substituted with 1, 2, 3, or 4 R e ;
- R 8 is hydrogen or C 1-4 alkyl
- R 6 , R 7 and R 8 are preferably as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is C 1-6 alkyl (e.g. methyl);
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (for example, ethyl or isopropyl), preferably isopropyl;
- R 7 is hydrogen, a substituted or unsubstituted C 1-6 alkyl group (the C 1-6 alkyl group is for example methyl or isopropyl; further, the substituted or unsubstituted C 1-6 alkyl group is for example Methyl or isopropyl) or -NR 7b R 7c (e.g. among them E.g ), the substituted C 1-6 alkyl group means that the C 1-6 alkyl group is substituted by 1, 2, 3, or 4 R 7d (for example, substituted by 1 R 7d );
- R 7b and R 7c are each independently hydrogen, substituted or unsubstituted C 1-4 alkyl (the C 1-4 alkyl such as ethyl, isopropyl or sec-butyl; further, the substituted or Unsubstituted C 1-4 alkyl such as ethyl, isopropyl, among them E.g ) Or substituted or unsubstituted C 3-6 cycloalkyl (the C 3-6 cycloalkyl group is, for example, cyclopropyl; further, the substituted or unsubstituted C 3-6 cycloalkyl group is, for example, cyclopropyl ), the substituted C 1-4 alkyl group and the substituted C 3-6 cycloalkyl group mean that the C 1-4 alkyl group and C 3-6 cycloalkyl group are each independently covered by 1, 2, 3 or 4 R d substitutions (for example, 1 R d substitution); preferably, one of R 7b and R 7c
- R 8 is hydrogen or C 1-4 alkyl (e.g. methyl), preferably hydrogen;
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. ethyl or isopropyl);
- R 7 is hydrogen or C 1-6 alkyl (e.g. methyl);
- R 8 is hydrogen or C 1-4 alkyl (e.g. methyl);
- R 6 , R 7 and R 8 are preferably as follows:
- R 6 is C 1-6 alkyl
- R 7 is C 1-6 alkyl
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is C 1-6 alkyl (e.g. methyl);
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is a substituted or unsubstituted C 1-6 alkyl group (the C 1-6 alkyl group is for example methyl; further, the substituted or unsubstituted C 1-6 alkyl group is for example methyl) or -NR 7b R 7c (e.g. E.g );
- the substituted C 1-6 alkyl group means that the C 1-6 alkyl group is substituted by 1, 2, 3, or 4 R 7d (for example, substituted by 1 R 7d );
- R 7b and R 7c are each independently hydrogen or substituted or unsubstituted C 1-4 alkyl (the C 1-4 alkyl group is, for example, isobutyl; further, the substituted or unsubstituted C 1-4 Alkyl such as E.g ), the substituted C 1-4 alkyl group means that the C 1-4 alkyl group is substituted by 1, 2, 3 or 4 Rd (for example, substituted by 1 Rd ); preferably, R 7b and One of R 7c is hydrogen;
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is C 1-6 alkyl (e.g. methyl);
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is C 1-6 alkyl (e.g. methyl) or -NR 7b R 7c (e.g. );
- R 7b and R 7c are each independently hydrogen, C 1-4 alkyl or C 3-6 cycloalkyl (the C 3-6 cycloalkyl such as cyclopropyl); preferably, in R 7b and R 7c One is hydrogen;
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is C 1-6 alkyl (e.g. methyl);
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is a substituted or unsubstituted C 1-6 alkyl group (the C 1-6 alkyl group is for example methyl; further, the substituted or unsubstituted C 1-6 alkyl group is for example methyl), -OR 7a (e.g. ) Or -NR 7b R 7c (e.g. among them E.g );
- the substituted C 1-6 alkyl group means that the C 1-6 alkyl group is substituted by 1, 2, 3, or 4 R 7d (for example, substituted by 1 R 7d );
- R 7a is hydrogen or a substituted or unsubstituted C 1-6 alkyl group (the C 1-6 alkyl group is, for example, isopropyl; further, the substituted or unsubstituted C 1-6 alkyl group is, for example, isopropyl Group), the substituted C 1-6 alkyl group means that the C 1-6 alkyl group is substituted by 1, 2, 3, or 4 R c (for example, substituted by 1 R c );
- R 7b and R 7c are each independently hydrogen, substituted or unsubstituted C 1-4 alkyl (the C 1-4 alkyl is, for example, isopropyl or sec-butyl; further, the substituted or unsubstituted C 1-4 alkyl such as isopropyl or among them E.g ), substituted or unsubstituted C 3-6 cycloalkyl (the C 3-6 cycloalkyl group is, for example, cyclopropyl or cyclopentyl; further, the substituted or unsubstituted C 3-6 cycloalkyl group For example cyclopropyl or among them E.g ), substituted or unsubstituted 5-6 membered heteroaryl (the 5-6 membered heteroaryl group is for example pyrazolyl, for example Further, the substituted or unsubstituted 5-6 membered heteroaryl group is for example ), the substituted C 1-4 alkyl, substituted C 3-6 cycl
- R 8 is hydrogen
- R 6 , R 7 and R 8 are as follows:
- R 6 is C 1-6 alkyl (e.g. isopropyl);
- R 7 is C 1-6 alkyl (e.g. methyl);
- R 8 is hydrogen
- X is O, and other variables are defined as described in any of the embodiments of the present invention.
- n 2 and n is 1, and the definitions of other variables are as described in any aspect of the present invention.
- R 1 is The definitions of other variables are as described in any aspect of the present invention.
- each R 6 is independently a C 1-6 alkyl group, preferably an isopropyl group, and other variables are defined as in any embodiment of the present invention Narrated.
- each R 7 is independently a C 1-6 alkyl group, and other variables are defined as described in any of the embodiments of the present invention.
- R 8 is hydrogen, and other variables are defined as described in any of the embodiments of the present invention.
- each group is defined as follows:
- ring A is
- X is O
- n 2;
- n 1;
- R 2 is hydrogen
- R 3 is hydrogen
- R 4 is -CH 2 -NR 4a R 4b (for example, -CH 2 -N(CH 3 ) 2 );
- R 4a and R 4b are each independently hydrogen or C 1-6 alkyl (e.g. methyl);
- Each R 6 is independently C 1-6 alkyl (e.g. methyl, ethyl, n-propyl or isopropyl, preferably isopropyl);
- Each R 7 is independently C 1-6 alkyl
- R 8 is hydrogen
- the labeled carbon atoms are in the S configuration, R configuration, or a mixture of the two.
- the compound represented by Formula I has any of the following structures:
- R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and * are defined as described in any of the foregoing schemes.
- the compound represented by Formula I has any of the following structures:
- R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and * are defined as described in any of the foregoing schemes.
- the compound represented by Formula I has any of the following structures:
- R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and * are defined as described in any of the foregoing schemes.
- ring A is preferably More preferably The definitions of other variables are as described in any aspect of the present invention.
- ring A is preferably More preferably The definitions of other variables are as described in any aspect of the present invention.
- ring A is preferably the definitions of other variables as described in any aspect of the present invention.
- the carbon atom marked with * is in the S configuration.
- the carbon atom marked with * is in the R configuration.
- the compound represented by Formula I has any of the following structures:
- the present invention also provides a method for preparing the compound represented by formula I as described above, which comprises the following steps: in an organic solvent (such as DMF and/or THF), the compound represented by formula II is combined with In the presence of a condensing agent (for example, one or more of HATU, PyBOP, and T3P) and a base (for example, TEA and/or DIPEA), the condensation reaction shown below is carried out to obtain the described formula I Compounds are sufficient; wherein ring A, X, m, n, R 1 , R 2 , R 3 , R 4 , R 5 and * are as defined above;
- a condensing agent for example, one or more of HATU, PyBOP, and T3P
- a base for example, TEA and/or DIPEA
- the method for preparing the compound represented by formula II may include the following steps: in an organic solvent (for example, DCM and/or dioxane), the compound represented by formula III in an acid (E.g. HCl and/or TFA) in the presence of HCl and/or TFA, carry out the de-Boc reaction shown below to obtain the compound shown in formula II; wherein, the definitions of ring A, X, m, n and * are as Mentioned before
- the preparation method of the compound represented by formula III may include the following steps: in an organic solvent (for example, one or more of THF, DCM and CH 3 CN), the compound represented by formula IV
- the compound represented by -1 and the compound represented by formula IV-2 undergo a condensation reaction as shown below in the presence of a base (such as TEA and/or DIPEA) to obtain the compound represented by formula III, namely Yes; where LG is a leaving group (such as chlorine or p-nitrophenyl), and rings A, X, m, n and * are as defined above;
- the preparation method of the compound represented by formula IV-1 may include the following steps: in an organic solvent (such as DCM and/or dioxane), the compound represented by formula V Carry out the de-Boc reaction shown below in the presence of an acid (such as HCl and/or TFA) to obtain the compound represented by formula IV-1; wherein the definition of ring A is as described above;
- an organic solvent such as DCM and/or dioxane
- an acid such as HCl and/or TFA
- the present invention also provides a compound or its tautomer, stereoisomer or isotopic derivative, or a pharmaceutically acceptable salt of any of the foregoing, or a crystal form or solvate of any of the foregoing,
- the compound is selected from any of the following structures:
- rings A, X, m, n and * are as described above.
- the present invention also provides a pharmaceutical composition, which comprises:
- At least one pharmaceutical excipient At least one pharmaceutical excipient.
- the present invention also provides a compound of Formula I or its tautomer, stereoisomer or isotopic derivative, or a pharmaceutically acceptable salt of any of the foregoing, or any of the foregoing Application of one of the crystal forms or solvates in the preparation of CDK7 inhibitors.
- the present invention also provides a compound of Formula I or its tautomer, stereoisomer or isotopic derivative, or a pharmaceutically acceptable salt of any of the foregoing, or any of the foregoing.
- a compound of Formula I or its tautomer, stereoisomer or isotopic derivative, or a pharmaceutically acceptable salt of any of the foregoing, or any of the foregoing The use of one crystal form or solvate in the preparation of medicines.
- the drug is a drug for the prevention and/or treatment of CDK7-mediated diseases, such as tumors, such as breast cancer, ovarian cancer, small cell lung cancer, and acute myeloid Leukemia, acute lymphocytic leukemia, bladder cancer, colon cancer, prostate cancer, epithelial sarcoma, soft tissue sarcoma.
- CDK7-mediated diseases such as tumors, such as breast cancer, ovarian cancer, small cell lung cancer, and acute myeloid Leukemia, acute lymphocytic leukemia, bladder cancer, colon cancer, prostate cancer, epithelial sarcoma, soft tissue sarcoma.
- the drug is a drug for preventing and/or treating tumors, such as breast cancer, ovarian cancer, small cell lung cancer, acute myeloid leukemia, or acute lymphocytic leukemia.
- the present invention also provides a method for preventing and/or treating a disease mediated by CDK7, which comprises administering to a subject in need of such treatment a therapeutically effective amount of the compound represented by formula I or its mutual variation Conformers, stereoisomers or isotopic derivatives, or pharmaceutically acceptable salts of any of the foregoing, or crystal forms or solvates of any of the foregoing.
- the CDK7-mediated disease may be a tumor, such as breast cancer, ovarian cancer, small cell lung cancer, acute myeloid leukemia, acute lymphoblastic leukemia, bladder cancer, colon cancer, prostate cancer, epithelial sarcoma , Soft tissue sarcoma.
- a tumor such as breast cancer, ovarian cancer, small cell lung cancer, acute myeloid leukemia, acute lymphoblastic leukemia, bladder cancer, colon cancer, prostate cancer, epithelial sarcoma , Soft tissue sarcoma.
- the present invention also provides a method for preventing and/or treating tumors, which comprises administering to a subject in need of such treatment a therapeutically effective amount of the compound represented by formula I or its tautomer, stereo Isomers or isotopic derivatives, or pharmaceutically acceptable salts of any of the foregoing, or crystal forms or solvates of any of the foregoing.
- the tumor may be breast cancer, ovarian cancer, small cell lung cancer, acute myeloid leukemia, acute lymphoblastic leukemia, bladder cancer, colon cancer, prostate cancer, epithelial sarcoma, and soft tissue sarcoma.
- tautomer refers to an isomer of a functional group resulting from the rapid movement of an atom in a molecule at two positions. For example, acetone and 1-propene-2-ol can be converted into each other by the rapid movement of hydrogen atoms on oxygen and ⁇ -carbon.
- stereoisomer refers to the isomers caused by the same order of interconnection of atoms or atomic groups in the molecule, but different spatial arrangements, such as cis-trans isomers, optical isomers, atropisomers and the like. These stereoisomers can be separated, purified and enriched by asymmetric synthesis methods or chiral separation methods (including but not limited to thin layer chromatography, rotation chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc.), and can also be obtained by It can be obtained by chiral resolution by forming bonds with other chiral compounds (chemical bonding, etc.) or salting (physical bonding, etc.). Optical isomers include enantiomers and diastereomers.
- isotopic derivative refers to the substitution of one or more atoms in a compound by one or more atoms having a specific atomic mass or mass number.
- isotopes that can be incorporated into the compound include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (e.g., 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O). , 18 F, 35 S and 36 Cl).
- Isotopic compounds can generally be prepared according to the methods described herein by substituting isotopically-labeled reagents for non-isotopically-labeled reagents. Typical examples of isotopic derivatives include deuterated compounds.
- pharmaceutically acceptable salt refers to a salt prepared from a compound with a relatively non-toxic, pharmaceutically acceptable acid or base.
- the base addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include, but are not limited to: lithium salt, sodium salt, potassium salt, calcium salt, aluminum salt, magnesium salt, zinc salt, bismuth salt, ammonium salt, and diethanolamine salt.
- the acid addition can be obtained by contacting the neutral form of the compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent.
- a pharmaceutically acceptable acid include inorganic acids, and the inorganic acids include, but are not limited to: hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, phosphoric acid, phosphorous acid, sulfuric acid, and the like.
- the pharmaceutically acceptable acids include organic acids, including but not limited to: acetic acid, propionic acid, oxalic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid , Fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, salicylic acid, tartaric acid, methanesulfonic acid, isonicotinic acid, acid citric acid, oleic acid , Tannic acid, pantothenic acid, hydrogen tartrate, ascorbic acid, gentisic acid, fumaric acid, gluconic acid, sugar acid, formic acid, ethanesulfonic acid, pamoic acid (i.e.
- crystal form means that the ions or molecules are arranged strictly and periodically in a three-dimensional space in a certain way, and have the regularity of periodic recurrence at a certain distance; due to the above-mentioned periodic arrangement, there may be multiple Crystal form, that is, polymorphism.
- solvate refers to a substance formed by combining a molecule with a stoichiometric or non-stoichiometric solvent.
- the solvent molecules in the solvate can exist in an ordered or non-ordered arrangement.
- the solvents include but are not limited to: water, methanol, ethanol and the like.
- halogen refers to fluorine, chlorine, bromine or iodine.
- alkyl refers to a saturated linear or branched monovalent hydrocarbon group having a specified number of carbon atoms, for example, C 1-4 alkyl refers to an alkyl group having 1 to 4 carbon atoms.
- alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and pentyl.
- the C 1-4 alkyl group can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl.
- the C 1-6 alkyl group can be a C 1-4 alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl. base.
- alkoxy refers to -OR X , where R X is an alkyl group as defined above.
- C 1- 4 alkoxy group may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy Oxy.
- cycloalkyl refers to a saturated monocyclic or polycyclic (for example, fused ring, spiro ring, or bridged ring) hydrocarbon group formed from carbon atoms.
- the cycloalkyl group is a monocyclic group.
- the C 3-6 cycloalkyl group can be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- heterocycloalkyl refers to a non-aromatic saturated or partially unsaturated monocyclic or polycyclic ring formed by carbon atoms and at least one heteroatom selected from the group consisting of N, O and S (for example, fused ring, spiro ring or bridge Ring) cyclic group.
- the heterocycloalkyl group is a saturated cyclic group.
- the heterocycloalkyl group is a monocyclic group.
- the heterocycloalkyl group is a saturated monocyclic group.
- Heterocycloalkyl groups can be connected to other parts of the molecule through heteroatoms or carbon atoms on the ring.
- heterocycloalkyl groups include, but are not limited to, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrothiophene- 2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl and 2-piperazinyl.
- the 4-6 membered heterocycloalkyl group may be 4, 5, or 6 membered heterocycloalkyl group.
- 4-membered heterocycloalkyl such as azetidinyl.
- 5-membered heterocycloalkyl examples include tetrahydrofuranyl, tetrahydropyrrolyl, and tetrahydrothienyl.
- 6-membered heterocycloalkyl groups include piperidinyl, morpholinyl, piperazinyl and the like.
- R g and R h together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-6 membered heterocycloalkyl group, so
- the 4-6 membered heterocyclic group has 0, 1, or 2 additional heteroatoms independently selected from N, O and S; the meaning of "extra" is clear, and refers to the -N R g R h (The nitrogen atom is marked with an underline).
- additional heteroatom is an oxygen atom; if -NR g R h is formed Then there are zero additional heteroatoms.
- heteroaryl refers to an aromatic cyclic group formed by a carbon atom and at least one heteroatom selected from N, O, and S.
- 5-membered heteroaryl groups such as furyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl or triazolyl;
- 6-membered heteroaryl groups such as pyrazinyl, pyridazinyl, pyridyl or Pyrimidinyl.
- x-y member in the cyclic group described herein means that the number of atoms in the ring is x-y.
- cyclopropyl is 3-membered
- tetrahydropyrrolyl is 5-membered
- piperidinyl is 6-membered.
- any variable such as R
- its definition in each case is independent.
- the group can optionally be substituted with up to two Rs, and R has independent options in each case.
- combinations of substituents and/or variables are only permitted if such combinations result in stable compounds.
- w is 0, 1 or 2
- each R is independently methyl or fluorine
- pharmaceutical excipients refers to excipients and additives used in the production of drugs and formulating prescriptions, and are all substances contained in pharmaceutical preparations except for active ingredients. Please refer to the Fourth Edition of the Pharmacopoeia of the People's Republic of China (2015 Edition), or Handbook of Pharmaceutical Excipients (Raymond C Rowe, 2009 Sixth Edition)
- treatment refers to therapeutic therapy.
- treatment refers to: (1) alleviating one or more biological manifestations of the disease or disease, (2) interfering with (a) one or more points in the biological cascade causing or causing the disease, or (b) ) One or more biological manifestations of the disease, (3) Improve one or more symptoms, effects or side effects related to the disease, or one or more symptoms, effects or side effects related to the disease or its treatment, Or (4) to slow down the development of the disease or one or more biological manifestations of the disease.
- terapéuticaally effective amount refers to an amount of a compound that is sufficient to effectively treat or prevent the diseases or conditions described herein when administered to a patient.
- the “therapeutically effective amount” will vary according to the compound, the condition and its severity, and the age of the patient to be treated, but can be adjusted by those skilled in the art as needed.
- subject refers to any animal that is about to or has received the administration of a compound or composition, mammals are preferred, and humans are preferred.
- mammal includes any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being the most preferred.
- the biological activity of the compounds of the present invention can be assessed by using any conventionally known methods. Appropriate detection methods are well known in the art. For example, the affinity activity, agonistic activity and/or antagonistic activity of the compound of the present invention for dopamine receptors, the pharmacokinetic activity and/or liver microsomal stability of the compound of the present invention, etc. can be tested by appropriate conventional methods.
- the detection method provided by the present invention is presented only as an example and does not limit the present invention.
- the compound of the present invention has activity in at least one of the detection methods provided by the present invention.
- the reagents and raw materials used in the present invention are all commercially available.
- PE petroleum ether
- EA ethyl acetate
- ACN acetonitrile
- Sphos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
- Pd 2 ( dba) 3 represents tris(dibenzylideneacetone) dipalladium
- HATU 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate
- LDA stands for lithium diisopropylamide
- THF stands for tetrahydrofuran
- PyBOP stands for benzotriazol-1-yl-oxytripyrrolidinyl phosphorus hexafluorophosphate
- DBU stands for 1,8-diazabicycloundecane -7-ene
- TEA stands for triethylamine
- DIPEA stands for N,
- the compound of the present invention has CDK7 inhibitory activity, and can be used as a reference for testing the compound's inhibitory activity against CDK7 in vitro, and can also be used to treat tumors and other diseases.
- Fig. 1 shows the change of the body weight of the experimental animals in the effect example 6 with the administration time.
- Figure 2 shows the tumor growth curve in Effect Example 6.
- the crude product 015095A5 400 mg, 1.07 mmol obtained in the previous step was dissolved in a 5N hydrochloric acid dioxane solution (5 mL), and the reaction solution was stirred and reacted at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a crude yellow solid 015095A6 (315 mg, >100%), which was directly used in the next reaction without purification.
- 015095A7 (101 mg, 0.207 mmol) was dissolved in 5N hydrochloric acid dioxane solution (10 mL), and the reaction solution was stirred and reacted at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a crude yellow oil of 015095A8 (65 mg, 81%), which was directly used in the next reaction without purification.
- SZ-015256A1, acetic acid (22 mL) and hydrazine hydrate (17 mL) obtained in the previous step were dissolved in ethanol (400 mL) and refluxed overnight. Spin off the ethanol in the system, adjust the pH to about 9 with saturated sodium bicarbonate, extract with dichloromethane (300 mL), dry the organic phase with anhydrous sodium sulfate and spin dry to obtain 20 g of SZ-015256A2.
- Step 4 8-isopropyl-2-methylpyrazolo[1,5-a][1,3,5]triazine-4(3H)-one
- Step 5 4-((8-isopropyl-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)piperidine-1-carboxy Tert-butyl ester
- Step 6 8-isopropyl-2-methyl-N-(piperidin-4-yl)pyrazolo[1,5-a][1,3,5]triazine-4-amine
- Step 7 (S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl 4-((8-isopropyl-2-methylpyrazolo[1,5-a][1 ,3,5)triazin-4-yl)amino)piperidine-1-carboxylate
- Step 1 6-Chloro-N 4 -isopropyl-2-methylpyrimidine-4,5-diamine
- Step 3 tert-Butyl 4-((9-isopropyl-2-methyl-9H-purin-6-yl)amino)piperidine-1-carboxylate
- Step 5 (S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl 4-((9-isopropyl-2-methyl-9H-purin-6-yl)amino)piperidine -1-carboxylate
- Step 6 (S)-Pyrrolidin-3-yl-4-((9-isopropyl-2-methyl-9H-purin-6-yl)amino)piperidine-1-carboxylate
- Step 7 (S,E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((9-isopropyl-2-methyl-9H- Purin-6-yl)amino)piperidine-1-carboxylate
- Step 6 tert-Butyl 4-((1-isopropyl-6-methyl-1H-imidazo[4,5-c]pyridinyl-4-yl)amino)piperidine-1-carboxylate
- Step 7 1-isopropyl-6-methyl-N-(piperidin-4-yl)-1H-imidazo[4,5-c]pyridin-4-amine
- Step 8 (S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl 4-((1-isopropyl-6-methyl-1H-imidazo[4,5-c]pyridine- 4-yl)amino)piperidine-1-carboxylate
- Step 9 (S)-pyrrolidin-3-yl 4-((1-isopropyl-6-methyl-1H-imidazo[4,5-c]pyridin-4-yl)amino)piperidine -1-formic acid
- Step 10 (S,E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((1-isopropyl-6-methyl-1H -Imidazo[4,5-c]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 3 4-((6-Chloro-3-isopropylimidazo[1,2-b]pyridazin-8-yl)amino)piperidine-1-carboxylic acid tert-butyl ester
- Step 4 4-((3-isopropyl-6-methylimidazo[1,2-b]pyridazin-8-yl)amino)piperidine-1-carboxylic acid tert-butyl ester
- Step 5 3-isopropyl-6-methyl-N-(piperidin-4-yl)imidazo[1,2-b]pyridazine-8-amine
- Step 6 (S)-1-(tert-Butoxycarbonyl)pyrrolidin-3-yl 4-((3-isopropyl-6-methylimidazo[1,2-b]pyridazine- 8-yl)amino)piperidine-1-carboxylate
- Step 7 (S)-1-(tert-Butoxycarbonyl)pyrrolidin-3-yl 4-((3-isopropyl-6-methylimidazo[1,2-b]pyridazine- 8-yl)amino)piperidine-1-carboxylate
- step 1
- step 1
- T 3 P solution (6.39 mL, 6 mmol, 50 wt% in EtOAc) was added to compound 015274A6 (160 mg, 0.39 mmol), trans-4-dimethylamino crotonate hydrochloride ( 160mg, 1mmol) and triethylamine (3.6mL, 25.8mmol) in acetonitrile (6mL) suspension.
- the resulting reaction mixture was stirred at 18-21°C for 16 hours.
- the reaction liquid was quenched with water, then solid sodium carbonate was added to a saturated state, and extracted with ethyl acetate (60 mL*3).
- step 1
- Trifluoroacetic acid (6 mL) was added to compound 015284A0 (015095A5) (630 mg, 1.69 mmol), and the resulting reaction mixture was heated to 90° C. and then stirred for 1 hour. The obtained reaction solution was spin-dried to dry the solvent, and then pumped by an oil pump for three minutes to obtain a yellow-brown oily product 015284A1 (580 mg, crude product), which was directly used in the next reaction.
- Trifluoroacetic acid (6 mL) was added to compound 015284A2 (390 mg), and the resulting reaction mixture was heated to 90°C and then stirred for 1 hour. The resulting reaction solution was spin-dried to dry the solvent, and then pumped with an oil pump for three minutes to obtain a yellow-brown oily product 015284A3 (360 mg, crude product), which was directly used in the next reaction.
- LCMS [M+H] + 387.11.
- Triethylamine (9 mL) was added in batches to a suspension of compound 015284A3 (360 mg) and 2-butynoic acid (110 mg, 1.28 mmol) in acetonitrile (6 mL), and the resulting reaction mixture was stirred at 16°C. Then the T 3 P solution (1.8 mL, 3 mmol, 50 wt% in EtOAc) was added to the above reaction solution in batches. The resulting reaction mixture was heated to 31°C and stirring continued for 16 hours. After the reaction liquid was quenched by adding water, solid sodium carbonate was added until the system was saturated, and then extracted with ethyl acetate (60 mL*3).
- step 1
- Trifluoroacetic acid (9 mL) was added to compound 015289A0 (015095A5) (1.6 g, 4.29 mmol), and the resulting reaction mixture was heated to 90° C. and then stirred for 1 hour. The resulting reaction solution was spin-dried to dry the solvent, and then pumped by an oil pump for three minutes to obtain a yellow-brown oily product 015289A1 (1.6 g, crude product), which was used directly in the next reaction.
- LCMS [M+H] + 274.09.
- Trifluoroacetic acid (9 mL) was added to compound 015289A2 (1.9 g), and the resulting reaction mixture was heated to 90°C and then stirred for 1 hour. The resulting reaction solution was spin-dried to dry the solvent, and then pumped by an oil pump for three minutes to obtain a yellow-brown oily product 015289A3 (1.3 g, crude product), which was directly used in the next reaction.
- LCMS [M+H] + 387.21.
- Triethylamine (16 mL) was added to a suspension of compound 015289A3 (310 mg, 0.63 mmol) and 2-butynoic acid (110 mg, 1.28 mmol) in acetonitrile (9 mL), and the resulting reaction mixture was stirred at 16°C. Then the T 3 P solution (1.8 mL, 3 mmol, 50 wt% in EtOAc) was added to the above reaction solution in batches. The resulting reaction mixture was heated to 31°C and stirring continued for 16 hours. After the reaction liquid was quenched by adding water, solid sodium carbonate was added until the system was saturated, and then extracted with ethyl acetate (60 mL*3).
- step 1
- step 1
- step 1
- step 1
- Step 3 Azetidine-3-yl 4-((3-isopropyl-5-methyl-3H-imidazo[4,5-b]pyridin-7-yl)amino)piperidine- 1-formate
- step 1
- step 1
- step 1
- step 1
- step 1
- SZ-015291A1 250 mg, 0.58 mmol was dissolved in dichloromethane (4 mL), trifluoroacetic acid (2 mL) was added to the system and stirred at room temperature overnight. After the reaction is completed, the crude product of SZ-015291A2 is obtained by spin-drying.
- step 1
- SZ-015295A4 (150mg, 0.33mmol) was dissolved in dichloromethane (4mL), trifluoroacetic acid (2ml) was added to the system and stirred overnight at room temperature. After the reaction was completed, the crude product of SZ-015295A5 was obtained by spin-drying.
- step 1
- Step 5 (S,E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((9-isopropyl-2-(1H-pyrazole) -4-yl)-9H-purin-6-yl)amino)piperidine-1-carboxylate
- step 1
- step 1
- step 1
- step 1
- step 1
- step 1
- step 1
- step 1
- step 1
- the compound triethylamine (13mL, 39mmol) was added in batches at 31 degrees Celsius to the compound p-nitrophenyl chloroformate (0.78g, 3.9mmol) and (S)-1-N-tert-butoxycarbonyl-3- Hydroxypyrrolidine (0.78g, 3.9mmol) in 1,4-dioxane (16mL) solution (the reaction system quickly formed a pale yellow suspension).
- the resulting reaction mixture was heated to 69 degrees Celsius and continued to stir for 3 hours (this suspension was directly used in the next reaction).
- Compound triethylamine (13mL, 39mmol) was added to compound 015342A7 (1.3g, 3.3mmol) at 31 degrees Celsius in batches.
- the reaction system was alkalized in a solution of 1,4-dioxane (6mL). Then, the suspension prepared above was added dropwise to the alkaline reaction system at 31 degrees Celsius. The resulting reaction mixture was heated to 69 degrees Celsius and stirring was continued for 16 hours. The obtained reaction solution was cooled to room temperature and quenched with water, and extracted with ethyl acetate (60 mL*3). The extracts were combined and dried with anhydrous MgSO 4 , filtered, and then spin-dried to dry the solvent. The residue was purified by column chromatography to obtain yellow oily product 015342A8 (0.9g). LCMS:[M+H] + 515.3
- step 1
- step 1
- step 1
- 015310A1 (1.9g, 5mmol) was dissolved in acetonitrile (50mL) and water (10mL), ruthenium trichloride (82mg, 5mol%) and NaIO 4 (3.2g, 15mmol) were added, stirred at room temperature for 12 hours, and added Water (100ml) was then extracted with ethyl acetate (30mL*3). After the organic phase was dried over sodium sulfate, the organic phase was spin-dried under reduced pressure to obtain a crude product, which was purified by flash silica gel column chromatography to obtain 015297A1 (1.2g, white solid). LCMS: [M+H] + 389.3.
- 015297A1 (1.2g, 3mmol) was dissolved in ethanol (40mL), NaBH(OAc) 3 (1.27g, 6mmol) was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was spin-dried under reduced pressure to obtain the crude product. The crude product was obtained by flash silica gel column chromatography. Purified by the method to obtain 015297A2 (380mg, white solid). LCMS: [M+H] + 391.4.
- the initial test concentration of the compound is 10 ⁇ M, 3-fold dilution, 10 concentrations, multiple well detection, and the pre-incubation time of the compound and enzyme is 60 minutes.
- the compound powder was dissolved in 100% DMSO, prepared as a 10 mM stock solution, diluted to 0.5 mM as the starting concentration, and continued to be diluted 3 times with DMSO to obtain 10 concentration gradient compound solutions.
- the compounds were prepared into 10 mM mother liquors with 100% DMSO respectively.
- the HCC70 and OVCAR3 cells were digested and counted. Dilute to the appropriate concentration according to the cell density. Pave a 96-well plate and add 100 ⁇ L of cells to each well. The medium well was used as a blank control (Min). Incubate overnight at 37°C in a 5% CO 2 incubator.
- a 200-fold compound stock solution was prepared with DMSO, and the compound was diluted with a growth medium to a 3-fold stock solution, that is, 3 ⁇ L of a 200-fold compound stock solution of different concentrations was added to 197 ⁇ L of the medium. Add 50 ⁇ L of diluted compound to each well and culture for 72 hours at 37°C and 5% CO 2.
Abstract
Description
化合物 | IC 50(nM) |
SZ-015200(WO2019099298实施例1) | 54.06 |
SZ-015201(WO2019099298实施例3) | 134.00 |
CT7001 | 33.20 |
SZ-015256 | 54.29 |
SZ-015095 | 128.30 |
SZ-015272 | 278.20 |
SZ-015273 | 44.46 |
SZ-0015268 | 23.56 |
SZ-015274 | 197.16 |
Claims (17)
- 一种如式I所示的化合物:或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物;X为O或NR a;R a为氢、甲基或乙基;m为1或2;n为1、2或3;R 2为氢或C 1-6烷基;R 3为氢或C 1-6烷基;R 4为氢、卤素、C 1-6烷基或-CH 2-NR 4aR 4b;R 4a和R 4b各自独立地为氢或C 1-6烷基;或者,R 4a和R 4b连同它们连接的氮原子一起形成取代或未取代的4-6元杂环烷基,所述4-6元杂环烷基具有0、1或2个独立选自N、O和S的额外杂原子,所述取代的4-6元杂环烷基是指所述4-6元杂环烷基被1、2、3或4个R b取代;每个R b独立地为卤素、羟基或C 1-4烷基;R 5为氢或C 1-6烷基;每个R 6独立地为氢、环丙基或C 1-6烷基;每个R 7独立地为氢、取代或未取代的C 1-6烷基、取代或未取代的苯基、取代或未取代的5-6元杂芳基、取代或未取代的C 3-6环烷基、-OR 7a或-NR 7bR 7c,所述的取代的C 1-6烷基、取代的C 3-6环烷基、取代的苯基以及取代的5-6元杂芳基是指所述C 1-6烷基、C 3-6环烷基、苯基和5-6元杂芳基各自独立地被1、2、3或4个R 7d取代;每个R 7d独立地为羟基、卤素、C 1-4烷基、-NR a1R a2或C 1-4烷氧基;R 7a为氢、取代或未取代的C 1-6烷基、取代或未取代的C 3-6环烷基、取代或未取代的4-6元杂环烷基或取代或未取代的5-6元杂芳基,所述取代的C 1-6烷基、取代的C 3-6环烷基、取代的4-6元杂环烷基以及取代的5-6元杂芳基是指所述C 1-6烷基、C 3-6环烷基、4-6元杂环烷基和5-6元杂芳基各自独立地被1、2、3或4个R c取代;每个R c独立地为羟基、卤素、C 1-4烷基、-NR c1R c2或C 1-4烷氧基;R 7b和R 7c各自独立地为氢、取代或未取代的C 1-4烷基、取代或未取代的C 3-6环烷基、取代或未取代的4-6元杂环烷基或取代或未取代的5-6元杂芳基,所述取代的C 1-4烷基、取代的C 3-6环烷基、取代的4-6元杂环烷基以及取代的5-6元杂芳基是指所述C 1-4烷基、C 3-6环烷基、4-6元杂环烷基和5-6元杂芳基各自独立地被1、2、3或4个R d取代;或者,R 7b和R 7c连同它们连接的氮原子一起形成取代或未取代的4-6元杂环烷基,所述4-6元杂环烷基具有0、1或2个独立选自N、O和S的额外杂原子,所述取代的4-6元杂环烷基是指所述4-6元杂环烷基被1、2、3或4个R e取代;每个R d独立地为羟基、卤素、C 1-4烷基、-NR d1R d2或C 1-4烷氧基;每个R e独立地为羟基、卤素、C 1-4烷基、-NR e1R e2或C 1-4烷氧基;每个R a1、R a2、R c1、R c2、R d1、R d2、R e1和R e2各自独立地为氢或C 1-4烷基;每个R 8独立地为氢或C 1-4烷基;当*标记的碳原子具有手性时,其为S构型、R构型或者两者的混合;所述4-6元杂环烷基和5-6元杂芳基中的杂原子个数独立地为1、2或3个,每个杂原子独立地选自N、O和S。
- 如权利要求1所述的化合物或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物,其特征在于,每个C 1-4烷基独立地为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,每个卤素独立地为氟、氯、溴或碘;和/或,每个C 1-6烷基独立地为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲 丁基或叔丁基;和/或,每个C 3-6环烷基独立地为环丙基、环丁基、环戊基或环己基;和/或,每个C 1-4烷氧基独立地为甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、仲丁氧基或叔丁氧基。
- 如权利要求1所述的化合物或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物,其特征在于,X为O或NR a;R a为氢、甲基或乙基;m为1或2;n为1、2或3;R 2为氢或C 1-6烷基;R 3为氢或C 1-6烷基;R 4为氢、卤素、C 1-6烷基或-CH 2-NR 4aR 4b;R 4a和R 4b各自独立地为氢或C 1-6烷基;或者,R 4a和R 4b连同它们连接的氮原子一起形成取代或未取代的4-6元杂环烷基,所述4-6元杂环烷基具有0、1或2个独立选自N、O和S的额外杂原子,所述取代的4-6元杂环烷基是指所述4-6元杂环烷基被1、2、3或4个R b取代;每个R b独立地为卤素、羟基或C 1-4烷基;R 5为氢或C 1-6烷基;每个R 6独立地为氢、环丙基或C 1-6烷基;每个R 7独立地为氢、C 1-6烷基、苯基、5-6元杂芳基、-OR 7a或-NR 7bR 7c;所述5-6元杂芳基中的杂原子个数为1、2或3个,每个杂原子独立地选自N、O和S;R 7a为氢或取代或未取代的C 1-6烷基,所述取代的C 1-6烷基是指所述C 1-6烷基被1、2、3或4个R c取代;每个R c独立地为羟基、卤素、C 1-4烷基或C 1-4烷氧基;R 7b和R 7c各自独立地为氢或取代或未取代的C 1-4烷基,所述取代的C 1-4烷基是指所述C 1-4烷基被1、2、3或4个R d取代;或者,R 7b和R 7c连同它们连接的氮原子一起形成取代或未取代的4-6元杂环烷基,所述4-6元杂环烷基具有0、1或2个独立选自N、O和S的额外杂原子,所述取代的4-6元杂环烷基是指所述4-6元杂环烷基被1、2、3或4个R e取代;每个R d独立地为羟基、卤素、C 1-4烷基或C 1-4烷氧基;每个R e独立地为羟基、卤素、C 1-4烷基或C 1-4烷氧基;每个R 8独立地为氢或C 1-4烷基;当*标记的碳原子具有手性时,其为S构型、R构型或者两者的混合。
- 如权利要求1所述的化合物或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物,其特征在于,当R 4a为C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当R 4b为C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当R 5为C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当R 6为C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基或异丙基;和/或,当R 7为取代或未取代的C 1-6烷基时,所述的C 1-6烷基为甲基、乙基或异丙基;和/或,当R 7为取代或未取代的C 3-6环烷基时,所述的C 3-6环烷基为环丙基;和/或,当R 7d为C 1-4烷氧基时,所述的C 1-4烷氧基为甲氧基;和/或,当R 7a为取代或未取代的C 1-6烷基时,所述的C 1-6烷基为异丙基;和/或,当R 7a为取代或未取代的C 3-6环烷基时,所述的C 3-6环烷基为环丙基;和/或,当R 7b和R 7c各自独立地为取代或未取代的C 1-4烷基时,所述的C 1-4烷基为乙基、异丙基或仲丁基;和/或,当R 7b和R 7c各自独立地为取代或未取代的C 3-6环烷基时,所述的C 3-6环烷基 为环丙基或环戊基;和/或,当R 7b和R 7c连同它们连接的氮原子一起形成取代或未取代的4-6元杂环烷基,所述4-6元杂环烷基为氮杂环丁基;和/或,当R c为C 1-4烷氧基时,所述的C 1-4烷氧基为甲氧基;和/或,当R d为C 1-4烷氧基时,所述的C 1-4烷氧基为甲氧基;和/或,当R e为C 1-4烷氧基时,所述的C 1-4烷氧基为甲氧基;和/或,当每个R a1、R a2、R c1、R c2、R d1、R d2、R e1和R e2各自独立地为C 1-4烷基时,所述的C 1-4烷基为甲基;和/或,当R 8为C 1-4烷基时,所述的C 1-4烷基为甲基。
- 如权利要求1所述的化合物或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物,其特征在于,当R 7a为取代或未取代的C 1-6烷基时,所述的取代或未取代的C 1-6烷基为异丙基;和/或,当R 7a为取代或未取代的C 3-6环烷基时,所述的取代或未取代的C 3-6环烷基为环丙基;和/或,当R c为-NR c1R c2时,所述的-NR c1R c2为-N(CH 3) 2;和/或,当R d为-NR d1R d2时,所述的-NR d1R d2为-N(CH 3) 2;和/或,当R e为-NR e1R e2时,所述的-NR e1R e2为-N(CH 3) 2;和/或,当R 7d为-NR a1R a2时,所述的-NR a1R a2为-N(CH 3) 2。
- 和/或,当R 4为-CH 2-NR 4aR 4b时,所述的-CH 2-NR 4aR 4b为-CH 2-N(CH 3) 2;和/或,当R 7为取代或未取代的C 1-6烷基时,所述的取代或未取代的C 1-6烷基为甲基、乙基、异丙基或-CH 2OH;和/或,当R 7为取代或未取代的C 3-6环烷基时,所述的取代或未取代的C 3-6环烷基为环丙基;
- 如权利要求1所述的化合物或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物,其特征在于,R a为氢;和/或,n为1;和/或,R 2为氢;和/或,R 3为氢;和/或,R 4为-CH 2-NR 4aR 4b;和/或,R 4a为C 1-6烷基;和/或,R 4b为C 1-6烷基;和/或,R 5为C 1-6烷基;和/或,每个R 7独立地为为氢、取代或未取代的C 1-6烷基、取代或未取代的5-6元杂芳基、取代或未取代的C 3-6环烷基、-OR 7a或-NR 7bR 7c,所述的取代的C 1-6烷基以及取代的5-6元杂芳基是指所述C 1-6烷基、C 3-6环烷基和5-6元杂芳基各自独立地被1、2、3或4个R 7d取代;和/或,每个R 7d独立地为羟基、-NR a1R a2或C 1-4烷氧基;和/或,R a1和R a2为C 1-4烷基;和/或,R 7a为氢、取代或未取代的C 1-6烷基或取代或未取代的C 3-6环烷基,所述取代的C 1-6烷基以及取代的C 3-6环烷基是指所述C 1-6烷基和C 3-6环烷基各自独立地被1、2、3或4个R c取代;和/或,R c为羟基、-NR c1R c2或C 1-4烷氧基;和/或,R c1和R c2为C 1-4烷基;和/或,R 7b和R 7c各自独立地为氢、取代或未取代的C 1-4烷基、取代或未取代的C 3-6环烷基或取代或未取代的5-6元杂芳基,所述取代的C 1-4烷基、取代的C 3-6环烷基以及取代的5-6元杂芳基是指所述C 1-4烷基、C 3-6环烷基和5-6元杂芳基各自独立地被1、2、3或4个R d取代;和/或,R d为羟基、-NR d1R d2或C 1-4烷氧基;和/或,R d1和R d2为C 1-4烷基。
- 如权利要求1-8中任一项所述的化合物或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物,其特征在于,R 6为C 1-6烷基;和/或,R 7为C 1-6烷基;和/或,R 8为氢。
- 一种药物组合物,其包含:(i)如权利要求1-10中任一项所述的化合物或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物;和(ii)至少一种药用辅料。
- 一种如权利要求1-10中任一项所述的化合物或其互变异构体、立体异构体或同位素衍生物,或前述任一者的药学上可接受的盐,或前述任一者的晶型或溶剂化物在制备药物中的应用。
- 如权利要求14所述的应用,其特征在于,所述的药物为用于预防和/或治疗CDK7介导的疾病的药物。
- 如权利要求15所述的应用,其特征在于,所述的CDK7介导的疾病为肿瘤,例如乳腺癌、卵巢癌、小细胞肺癌、急性髓系白血病、急性淋巴细胞白血病、膀胱癌、结肠癌、***癌、上皮肉瘤、软组织肉瘤。
- 如权利要求14所述的应用,其特征在于,所述的药物为用于预防和/或***的药物,所述肿瘤例如乳腺癌、卵巢癌、小细胞肺癌、急性髓系白血病、急性淋巴细胞白血病、膀胱癌、结肠癌、***癌、上皮肉瘤、软组织肉瘤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227024992A KR20220137002A (ko) | 2019-12-20 | 2020-12-18 | 헤테로고리 화합물 및 그의 약제학적 조성물, 제조 방법, 중간체 및 용도 |
EP20903847.0A EP4079733A1 (en) | 2019-12-20 | 2020-12-18 | Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof |
CA3161869A CA3161869A1 (en) | 2019-12-20 | 2020-12-18 | Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof |
JP2022538335A JP2023507028A (ja) | 2019-12-20 | 2020-12-18 | 複素環式化合物とその医薬組成物、調製方法、中間体及び使用 |
US17/786,280 US20230115907A1 (en) | 2019-12-20 | 2020-12-18 | Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and use thereof |
AU2020404326A AU2020404326A1 (en) | 2019-12-20 | 2020-12-18 | Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911329611 | 2019-12-20 | ||
CN201911329611.X | 2019-12-20 | ||
CN202010312893.9 | 2020-04-20 | ||
CN202010312893 | 2020-04-20 | ||
CN202010882490 | 2020-08-28 | ||
CN202010882490.8 | 2020-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021121390A1 true WO2021121390A1 (zh) | 2021-06-24 |
Family
ID=76383456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/137618 WO2021121390A1 (zh) | 2019-12-20 | 2020-12-18 | 杂环化合物及其药物组合物、制备方法、中间体和应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230115907A1 (zh) |
EP (1) | EP4079733A1 (zh) |
JP (1) | JP2023507028A (zh) |
KR (1) | KR20220137002A (zh) |
CN (1) | CN113004285A (zh) |
AU (1) | AU2020404326A1 (zh) |
CA (1) | CA3161869A1 (zh) |
WO (1) | WO2021121390A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022033552A1 (zh) * | 2020-08-12 | 2022-02-17 | 隆泰申医药科技(南京) 有限公司 | Cdk激酶抑制剂、其制备方法、药物组合物和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005548A1 (en) * | 2004-07-15 | 2006-01-19 | F. Hoffmann-La Roche Ag | Novel 2,6-diaminopyridine-3-one derivatives |
CN1880317A (zh) * | 2002-09-04 | 2006-12-20 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
WO2008130570A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US20100280065A1 (en) | 2007-09-12 | 2010-11-04 | Centre National De La Recherche Scientifique | Perharidines as cdk inhibitors |
WO2015154022A1 (en) * | 2014-04-05 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN107530329A (zh) * | 2015-03-09 | 2018-01-02 | 奥瑞基尼探索技术有限公司 | 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物 |
WO2019099298A1 (en) | 2017-11-16 | 2019-05-23 | Eli Lilly And Company | Compounds useful for inhibiting cdk7 |
WO2019197549A1 (en) | 2018-04-11 | 2019-10-17 | Qurient Co., Ltd. | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7674804B2 (en) * | 2006-06-29 | 2010-03-09 | Hoffmann-La Roche Inc. | Pyrimidine and quinazoline derivatives as SST5 modulators |
-
2020
- 2020-12-18 WO PCT/CN2020/137618 patent/WO2021121390A1/zh unknown
- 2020-12-18 JP JP2022538335A patent/JP2023507028A/ja active Pending
- 2020-12-18 CN CN202011507434.2A patent/CN113004285A/zh active Pending
- 2020-12-18 CA CA3161869A patent/CA3161869A1/en active Pending
- 2020-12-18 EP EP20903847.0A patent/EP4079733A1/en not_active Withdrawn
- 2020-12-18 AU AU2020404326A patent/AU2020404326A1/en active Pending
- 2020-12-18 KR KR1020227024992A patent/KR20220137002A/ko unknown
- 2020-12-18 US US17/786,280 patent/US20230115907A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1880317A (zh) * | 2002-09-04 | 2006-12-20 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
WO2006005548A1 (en) * | 2004-07-15 | 2006-01-19 | F. Hoffmann-La Roche Ag | Novel 2,6-diaminopyridine-3-one derivatives |
WO2008130570A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US20100280065A1 (en) | 2007-09-12 | 2010-11-04 | Centre National De La Recherche Scientifique | Perharidines as cdk inhibitors |
WO2015154022A1 (en) * | 2014-04-05 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN107530329A (zh) * | 2015-03-09 | 2018-01-02 | 奥瑞基尼探索技术有限公司 | 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物 |
WO2019099298A1 (en) | 2017-11-16 | 2019-05-23 | Eli Lilly And Company | Compounds useful for inhibiting cdk7 |
WO2019197549A1 (en) | 2018-04-11 | 2019-10-17 | Qurient Co., Ltd. | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
Non-Patent Citations (9)
Title |
---|
"Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
ASGHAR UWITKIEWICZ A KTURNER N C ET AL.: "The history and future of targeting cyclin-dependent kinases in cancer therapy", NAT REV DRUG DISCOV, no. 2, 2015, pages 130 - 146, XP055655676, DOI: 10.1038/nrd4504 |
BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 |
CHIPUMURO EMARCO ECHRISTENSEN CLKWIATKOWSKI NZHANG THATHEWAY CM ET AL.: "CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer", CELL, vol. 159, 2014, pages 1126 - 39, XP055421958, DOI: 10.1016/j.cell.2014.10.024 |
CHRISTENSEN CLKWIATKOWSKI NABRAHAM BJCARRETERO JAL-SHAHROUR FZHANG T ET AL.: "Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor", CANCER CELL, vol. 26, 2014, pages 909 - 22, XP055557183, DOI: 10.1016/j.ccell.2014.10.019 |
KELSO TWBAUMGART KEICKHOFF JALBERT TANTRECHT CLEMCKE S ET AL.: "Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells", MOL CELL BIOL, vol. 34, 2014, pages 3675 - 3688, XP055494098, DOI: 10.1128/MCB.00595-14 |
RAYMOND C ROWE: "Pharmacopoeia of The People's Republic of China", vol. 4 |
WANG YZHANG TKWIATKOWSKI NABRAHAM BJLEE TIXIE S ET AL.: "CDK7dependent transcriptional addiction in triple-negative breast cancer", CELL, vol. 163, 2015, pages 174 - 86, XP029280470, DOI: 10.1016/j.cell.2015.08.063 |
YEE ANICHOLS MAWU LHALL FLKOBAYASHI RXIONG Y: "Molecular cloning of CDK7-associated human MAT1, a cyclin-dependent kinase-activating kinase (CAK) assembly factor", CANCER RES, vol. 55, 1995, pages 6058 - 6062 |
Also Published As
Publication number | Publication date |
---|---|
EP4079733A1 (en) | 2022-10-26 |
CA3161869A1 (en) | 2021-06-24 |
KR20220137002A (ko) | 2022-10-11 |
CN113004285A (zh) | 2021-06-22 |
AU2020404326A1 (en) | 2022-08-11 |
JP2023507028A (ja) | 2023-02-20 |
US20230115907A1 (en) | 2023-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI675028B (zh) | 做為週期素依賴型激酶(cdk)抑制劑之2-h-吲唑衍生物及其醫療用途 | |
AU2018226315B2 (en) | FGFR inhibitor and application thereof | |
WO2020239077A1 (zh) | 含氮杂环类衍生物调节剂、其制备方法和应用 | |
WO2021218110A1 (zh) | 一类苯并噻唑基联芳基类化合物、制备方法和用途 | |
KR101661405B1 (ko) | 사이클린 의존성 키나제 억제제로서의 신규 피라졸로피리미딘 유도체 | |
WO2020156243A1 (zh) | Shp2抑制剂及其应用 | |
AU2015238296B2 (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors | |
KR102429355B1 (ko) | 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도 | |
JP6321821B2 (ja) | 2,3,4,6−4置換ベンゼン−1,5−ジアミン誘導体、その製造方法および医薬品における使用 | |
CN113286794A (zh) | Kras突变蛋白抑制剂 | |
HUE033177T2 (en) | Pyrazine is a carboxamide compound | |
CN109311846B (zh) | 作为nik抑制剂的新的6元杂芳族取代的氰基吲哚衍生物 | |
CN109641882A (zh) | 作为nik抑制剂的杂芳族衍生物 | |
JP2017508779A5 (zh) | ||
TWI780077B (zh) | 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用 | |
CN110964023B (zh) | 稠合四环类化合物及其在药物中的应用 | |
WO2023280237A1 (zh) | 一种磷酸酶降解剂的合成和应用 | |
WO2021121390A1 (zh) | 杂环化合物及其药物组合物、制备方法、中间体和应用 | |
JP2021504334A (ja) | ピラゾロピリジノン化合物 | |
US10807983B2 (en) | Imidazo-fused heterocycles and uses thereof | |
WO2022271630A1 (en) | Egfr inhibitors | |
KR20240019071A (ko) | N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법 | |
CN116969944A (zh) | 乙氨基取代的三环杂环化合物及其组合物、制剂和用途 | |
WO2023008577A1 (ja) | Ras/Raf結合阻害化合物 | |
CN117304182A (zh) | 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20903847 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3161869 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022538335 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020903847 Country of ref document: EP Effective date: 20220720 |
|
ENP | Entry into the national phase |
Ref document number: 2020404326 Country of ref document: AU Date of ref document: 20201218 Kind code of ref document: A |